Summary
Boston Scientific Corporation (BSX) has announced a significant strategic move with the acquisition of Advanced Bionics Corporation for an initial cash payment of approximately $740 million, plus potential earnout payments estimated at $2.0 billion. This acquisition positions BSX to enter the rapidly growing implantable microelectronic device market, bolstering its technology portfolio in areas such as neurostimulators and cochlear implants, which address neurological disorders. To manage the funding for this acquisition, which was initially financed through commercial paper, Boston Scientific is concurrently launching a public offering of $500 million in senior notes. These proceeds are earmarked for repaying existing commercial paper and general corporate purposes, demonstrating a proactive approach to financial management following a substantial strategic investment.
Key Highlights
- 1Boston Scientific acquired Advanced Bionics Corporation for approximately $740 million in cash, plus significant potential earnout payments.
- 2The acquisition marks Boston Scientific's entry into the implantable microelectronic device market, targeting neurological disorders.
- 3Advanced Bionics' technology includes neurostimulators, drug pumps, and cochlear implants.
- 4The acquisition's earnout structure is tied to future sales performance and profitability across four technology platforms, with an estimated future contingent consideration of $2.0 billion.
- 5Boston Scientific is issuing $500 million in senior notes to repay commercial paper used to fund the Advanced Bionics acquisition and for general corporate purposes.
- 6The initial purchase of Advanced Bionics was funded by approximately $740 million in commercial paper borrowings.